d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neural Transmission / General Section JNT

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/BF01276429PMID 7865165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior

  2005cited by this paper
• Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump.

  1992influential reference
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Limbic/mesolimbic connections and the pathogenesis of schizophrenia.

  1991cited by this paper
• Amino acid patterns in schizophrenia: some new findings.

  1990cited by this paper
• Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.

  1990cited by this paper
• An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy.

  1990cited by this paper
• D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

  1990cited by this paper
• D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics.

  1989cited by this paper
• Creation, evolution, and biological psychiatry.

  1988cited by this paper
• Glycine therapy of schizophrenia.

  1988cited by this paper
• An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release

  1987cited by this paper
• Evidence for an endogenous peptide ligand for the phencyclidine receptor.

  1984cited by this paper
• Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.

  1980cited by this paper
• Model psychoses and schizophrenia.

  1962cited by this paper

• Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis

  2025cites this paper
• Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia

  2024cites this paper
• Cycloserine-induced psychosis in patients with drug-resistant tuberculosis: a systematic review of case reports

  2023cites this paper
• Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia

  2021cites this paper
• Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia

  2021cites this paper
• Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophrenia.

  2020cites this paper
• A Review of the Actions of D-cycloserine, a Putative Nootropic Agent, at the NMDA Receptor Complex-Associated Glycine Binding Site

  2020cites this paper
• Effects of glutamate-related drugs on anxiety and compulsive behavior in rats with obsessive-compulsive disorder

  2020cites this paper
• Glutamate modulators for treatment of schizophrenia

  2019cites this paper
• Glycine enhances expression of adiponectin and IL-10 in 3T3-L1 adipocytes without affecting adipogenesis and lipolysis

  2018cites this paper
• D-cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions Detailed Study Protocol Principal Investigator: Donald Goff, MD Purpose of the Study Specific Aims and Design: Antipsychotic-resistant delusions in schizophrenia are common, are often distressing, and increase the risk for inca

  2018cites this paper
• Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study

  2017cites this paper
• The Therapeutic Role of d-Cycloserine in Schizophrenia.

  2016cites this paper
• Explorer A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder : Altered L-serine level associated with disruption of PSAT 1 gene expression

  2016cites this paper
• Measuring Brain Serine With Proton Magnetic Resonance Spectroscopy At 3.0 Tesla

  2016cites this paper
• Biological function of D-aspartate in the mammalian brain

  2016cites this paper
• D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity

  2016cites this paper
• 5-HT7 Receptor Neuroprotection against Excitotoxicity in the Hippocampus

  2014cites this paper
• d-Cycloserine augmentation of cognitive remediation in schizophrenia.

  2014cites this paper
• NMDA pathology and treatment of schizophrenia.

  2014cites this paper
• Pharmacological approaches to treating negative symptoms: a review of clinical trials.

  2013cites this paper
• The Hypothesis of NMDA Receptor Hypofunction for Schizophrenia

  2012cites this paper
• D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.

  2012cites this paper
• Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.

  2012cites this paper
• The Glutamate Hypothesis of Schizophrenia Therapeutic Implications

  2012cites this paper
• A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression.

  2011cites this paper
• Contributions of Glutamate and GABA Systems to the Neurobiology and Treatment of Schizophrenia

  2011cites this paper
• The role of NMDA receptors in the signal attenuation rat model of obsessive–compulsive disorder

  2010cites this paper
• Characterization of the D-amino acid oxidase interactome

  2010cites this paper
• The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

  2010cites this paper
• Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.

  2010cites this paper
• The role of the glutamatergic system in psychiatric behavioral endophenotypes in mice : implications for schizophrenia.

  2009influential citation
• Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

  2009cites this paper
• Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia

  2009cites this paper
• AN FMRI STUDY EXAMINING THE EFFECTS OF ACUTE D-CYCLOSERINE ADMINISTRATION ON BRAIN ACTIVATIONS AND COGNITIVE FUNCTIONING IN SPIDER PHOBIA

  2009cites this paper
• New Approaches to Treatment of Schizophrenia by Enhancing N -methyl- D -aspartate Neurotransmission

  2008cites this paper
• Development of a liposome formulation for D-cycloserine local delivery.

  2008cites this paper
• Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls

  2008cites this paper
• Development of a Liposome Formulation for D-Cycloserine Local Delivery

  2008cites this paper
• The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

  2007cites this paper
• D-serine: a new word in the glutamatergic neuro-glial language

  2007cites this paper
• Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site

  2007influential citation
• Glutamatergic drugs for schizophrenia.

  2006cites this paper
• Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.

  2006cites this paper
• Glutamatergic mechanisms in schizophrenia: Current concepts

  2006cites this paper
• Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.

  2005cites this paper
• The glycine antagonist (+)-HA-966 injected into the nucleus accumbens stimulates locomotion in mice

  2005cites this paper
• A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

  2005cites this paper
• Glutamate and Schizophrenia and the N -Methyl- d -Aspartate Receptor Hypofunction Hypothesis

  2005cites this paper
• D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.

  2005cites this paper
• N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives

  2005cites this paper
• Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.

  2005cites this paper
• An ionotropic but not a metabotropic glutamate agonist potentiates the pharmacological effects of olanzapine in the rat

  2005cites this paper
• NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia.

  2004cites this paper
• New antipsychotics and schizophrenia: a review on efficacy and side effects.

  2004cites this paper
• Effects of D-cycloserine on negative symptoms in schizophrenia.

  2004cites this paper
• High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.

  2004cites this paper
• The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective.

  2004cites this paper
• Schizophrenia as a disorder of neuroplasticity.

  2004cites this paper
• Schizophrenia: from dopamine to glutamate and back.

  2004cites this paper
• The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

  2004cites this paper
• D-serine metabolism: an evolutionary perspective

  2004cites this paper
• Dietary glycine prevents chemical-induced experimental colitis in the rat.

  2003cites this paper
• Synapse-Associated Protein 90/Postsynaptic Density-95-Associated Protein (SAPAP) is Expressed Differentially in Phencyclidine-Treated Rats and is Increased in the Nucleus Accumbens of Patients with Schizophrenia

  2003cites this paper
• Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.

  2003cites this paper
• Aktuelle Forschungsaspekte zur Ätiopathogenese der Schizophrenien

  2003cites this paper
• Glutamatergic mechanisms in schizophrenia.

  2003cites this paper
• Pharmacogenomics of schizophrenia: Towards personalized psychiatry

  2003cites this paper
• D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.

  2002cites this paper
• Homer 1a Gene Expression Modulation by Antipsychotic Drugs: Involvement of the Glutamate Metabotropic System and Effects of D-Cycloserine

  2002cites this paper
• Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder.

  2001cites this paper
• Treatment of Comorbid Tuberculosis and Depression.

  2001cites this paper
• [Glutamatergic neurotransmission in schizophrenics].

  2001cites this paper
• In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists.

  2000cites this paper
• d -Cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function

  2000cites this paper
• Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications.

  2000cites this paper
• N-Methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade.

  2000cites this paper
• Glutamate receptor expression in schizophrenic brain.

  2000cites this paper
• Kynurenine metabolism in Alzheimer's disease

  1999cites this paper
• Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

  1999cites this paper
• Characterization of MK-801-induced behavior as a putative rat model of psychosis.

  1999cites this paper
• Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

  1999cites this paper
• D-Cycloserine Increases Positive Symptoms in Chronic Schizophrenic Patients When Administered in Addition to Antipsychotics: A Double-Blind, Parallel, Placebo-Controlled Study

  1999cites this paper
• NMDA receptor antagonists acting at the glycineB site in rat models for antipsychotic-like activity

  1999cites this paper
• Glutamate in CNS disorders as a target for drug development: an update.

  1998cites this paper
• Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.

  1998cites this paper
• The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes.

  1998cites this paper
• Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

  1998cites this paper
• Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

  1998cites this paper
• Schizophrenia and glutamatergic transmission.

  1998cites this paper
• A two-process theory of schizophrenia: evidence from studies in post-mortem brain.

  1997cites this paper
• Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia

  1997cites this paper
• Antibiotics: Neuropsychiatric Effects and Psychotropic Interactions

  1997cites this paper
• Glutamate in schizophrenia: clinical and research implications.

  1997cites this paper
• D-cycloserine added to clozapine for patients with schizophrenia.

  1996cites this paper
• Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.

  1996cites this paper
• Mechanisms of action of atypical antipsychotic drugs: a critical analysis

  1996cites this paper
• Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia

  1996cites this paper
• The Glutamatergic Dysfunction Hypothesis for Schizophrenia

  1996cites this paper
• D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.

  1996cites this paper